## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.6% below STRENGTH zone (3.0-6.0%); PEG 1.50 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($112.43)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. DaVita Inc. $DVA Shares Sold by Franklin Resources Inc.**
- Source: MarketBeat | 20251203T190816 | Neutral | Relevance: 99%
-  Franklin Resources Inc. reduced its stake in DaVita Inc. (NYSE:DVA) by 51.2% in the second quarter, selling over 26,000 shares. DaVita recently reported Q3 earnings that missed analyst expectations with $2.51 EPS on $3.42 billion revenue, and its FY2025 EPS guidance is set between $10.35-$11.15. The stock has a consensus "Reduce" rating with a target price of $148, and institutional ownership remains high at 90.12%.

**2. Catalyzing Change in Specialty Care: DaVita Shares Vision for Technology Transformation**
- Source: ACCESS Newswire | 20251202T103500 | Bullish | Relevance: 99%
- DaVita shared its vision for technology transformation in specialty care, emphasizing how technology can help address healthcare fragmentation for the 129 million Americans living with chronic conditions. Joel Haugen, Chief Product Officer for DaVita, highlighted the significant medical spend in specialty care and the potential of solutions like the DaVita Care Connect mobile app to enhance patient engagement through user-friendly interfaces. The article stresses the need for intentional change, prioritizing the experience of both patients and care teams, and fostering collaboration among stakeholders to scale solutions and reduce care fragmentation.

**3. Catalyzing Change in Specialty Care: DaVita Shares Vision for Technology Transformation**
- Source: Yahoo Finance | 20251202T153500 | Bullish | Relevance: 98%
- DaVita (DVA) highlights its vision for leveraging technology to transform specialty care, addressing the fragmentation prevalent in chronic disease management. Joel Haugen, chief product officer, emphasized that specialty care accounts for 90% of medical spend and showcased DaVita Care Connect as an example of technology enhancing patient engagement, adherence, and overall experience. The company stresses the importance of designing user-friendly solutions for both patients and care teams, as well as fostering collaboration among stakeholders to scale these technological advancements.

**4. DaVita - More Volatile But Better Upside Than Fresenius (NYSE:DVA)**
- Source: Seeking Alpha | 20251203T093000 | Bullish | Relevance: 97%
- DaVita (DVA) is rated a speculative 'Buy' due to undervaluation and its dominant US dialysis network, despite earnings volatility and reliance on Medicare reimbursement. Trading below 11.5x P/E, DVA offers potential double-digit annual returns if it regains historical valuation multiples. Key risks include Medicare rate cuts, earnings misses, and high leverage, necessitating careful position sizing for risk-tolerant investors.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 4 ($55.95M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $56M sold (4 transactions in 90 days).
2. High short interest (21.2%, 8.1 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 13.7% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.50 suggests fair value with growth premium. Forward P/E 9.3x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($56.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.3B |
| Beta | 0.99 |
| 52W Range | $113.97 - $179.60 |
| Short Interest | 21.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.50 |
| Forward P/E | 9.3 |
| Current P/E | 11.1 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.4% to -2.6% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.6pp (needs >3.0% for momentum thesis). Below SMA200 (0.86x), long-term trend not supportive. RSI neutral at 42.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.62% (CS: 23) | Weak |
| RSI_14 | 41.9 | Neutral |
| MACD Histogram | 0.30 | Bullish |
| vs SMA20 | 0.986x | Below |
| vs SMA50 | 0.950x | Below |
| vs SMA200 | 0.863x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $118.25
- **Stop Loss:** $112.43 (4.9% risk)
- **Target:** $124.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 163
- **Position Value:** $19,274.75
- **Portfolio %:** 19.27%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite. VIX at 16 is below median, showing calm, but breadth is only moderate and put/call is neutral, suggesting neither strong bullish nor defensive extremes. Key drivers are rising Fed rate-cut odds from soft ADP jobs data, mixed earnings across sectors, and ongoing AI/tech strength offset by caution in cyclicals and banks. Positioning should remain selective and neutral, awaiting more decisive macro or earnings signals.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*